NCT04102098 2026-03-19
IMbrave050
Hoffmann-La Roche
Phase 3 Active not recruiting
Clinical Trials
19 trialsNCT02519348 2026-02-17
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
MedImmune LLC
Phase 2 Active not recruiting
NCT04862949 2025-12-12
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
CHA University
Completed
NCT04487067 2025-09-22
AMETHISTA
Hoffmann-La Roche
Phase 3 Completed
NCT04732286 2025-05-08
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
Hoffmann-La Roche
Phase 3 Terminated
NCT05776875 2025-01-15
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
Yale University
Phase 2 Terminated
NCT00410956 2024-12-10
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04541173 2024-06-05
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03434379 2023-10-23
IMbrave150
Hoffmann-La Roche
Phase 3 Completed
NCT01180959 2022-11-07
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00867321 2022-04-19
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT00335829 2021-08-13
Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Yale University
Phase 2 Completed
NCT00049322 2020-09-01
Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01010126 2019-01-25
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00881751 2017-09-11
Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer
Medical University of South Carolina
Phase 2 Completed
NCT00055692 2016-02-29
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00365391 2015-07-09
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00242502 2013-05-06
Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00287222 2011-07-15
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
University of Arkansas
Phase 2 Completed